Biotie completes Phase 2b Parkinson’s disease trial enrolment ahead of schedule

Biotie Therapies (OMXH: BTH1V) noted this morning that its week, double-blind, placebo-controlled, dose-finding study with Tozadenant (SYN115) in patients suffering Parkinson’s Disease has reached target enrolment of 420 patients suffering from levodopa related end of dose wearing off ahead of schedule. The trial is conducted in US, Canada, Chile, Argentina, Ukraine and Romania and should report topline data at the end of this year. UCB Pharma S.A. has an exclusive worldwide license for the orally administered adenosine 2a (A2a) antagonist and would be responsible for further development in the indication if results so warrant.